Millennium Management’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $39.8M | Buy |
1,253,532
+40,827
| +3% | +$1.11M | 0.02% | 1003 |
|
|
2025
Q4 | $32.9M | Buy |
1,212,705
+237,510
| +24% | +$6.26M | 0.01% | 1105 |
|
|
2025
Q3 | $25.2M | Buy |
975,195
+497,968
| +104% | +$11.5M | 0.01% | 1417 |
|
|
2025
Q2 | $9.71M | Buy |
477,227
+77,295
| +19% | +$1.5M | ﹤0.01% | 2285 |
|
|
2025
Q1 | $7.26M | Buy |
399,932
+306,330
| +327% | +$6.84M | ﹤0.01% | 2500 |
|
|
2024
Q4 | $2.37M | Sell |
93,602
-14,501
| -13% | -$394K | ﹤0.01% | 3490 |
|
|
2024
Q3 | $3.67M | Buy |
108,103
+64,353
| +147% | +$2.45M | ﹤0.01% | 3120 |
|
|
2024
Q2 | $1.62M | Sell |
43,750
-164,501
| -79% | -$6.21M | ﹤0.01% | 3719 |
|
|
2024
Q1 | $8.74M | Buy |
208,251
+197,254
| +1,794% | +$8.1M | ﹤0.01% | 2320 |
|
|
2023
Q4 | $436K | Sell |
10,997
-147,160
| -93% | -$4.33M | ﹤0.01% | 4722 |
|
|
2023
Q3 | $4.35M | Buy |
158,157
+137,417
| +663% | +$4.31M | ﹤0.01% | 2823 |
|
|
2023
Q2 | $704K | Buy |
+20,740
| New | +$699K | ﹤0.01% | 4309 |
|
|
2023
Q1 | – | Sell |
-34,351
| Closed | -$1.53M | – | 6427 |
|
|
2022
Q4 | $1.53M | Buy |
+34,351
| New | +$1.23M | ﹤0.01% | 3790 |
|
|
2022
Q3 | – | Sell |
-143,343
| Closed | -$3.87M | – | 7102 |
|
|
2022
Q2 | $3.87M | Buy |
143,343
+35,642
| +33% | +$1.04M | ﹤0.01% | 3053 |
|
|
2022
Q1 | $3.67M | Buy |
107,701
+68,030
| +171% | +$2.17M | ﹤0.01% | 3274 |
|
|
2021
Q4 | $1.53M | Buy |
+39,671
| New | +$1.73M | ﹤0.01% | 4012 |
|
|
2021
Q2 | – | Sell |
-505,163
| Closed | -$10.4M | – | 6573 |
|
|
2021
Q1 | $10.4M | Buy |
505,163
+299,241
| +145% | +$6.87M | 0.01% | 1731 |
|
|
2020
Q4 | $3.61M | Buy |
+205,922
| New | +$3.71M | ﹤0.01% | 2759 |
|
|
2020
Q3 | – | Sell |
-430,564
| Closed | -$5.6M | – | 4483 |
|
|
2020
Q2 | $5.6M | Buy |
+430,564
| New | +$1.91M | 0.01% | 1661 |
|
|
2019
Q1 | – | Sell |
-25,292
| Closed | -$75K | – | 4009 |
|
|
2018
Q4 | $75K | Sell |
25,292
-96,525
| -79% | -$474K | ﹤0.01% | 3577 |
|
|
2018
Q3 | $824K | Sell |
121,817
-23,380
| -16% | -$164K | ﹤0.01% | 2977 |
|
|
2018
Q2 | $1.1M | Buy |
145,197
+18,205
| +14% | +$243K | ﹤0.01% | 2780 |
|
|
2018
Q1 | $4.44M | Sell |
126,992
-22,443
| -15% | -$870K | 0.01% | 1885 |
|
|
2017
Q4 | $6.37M | Buy |
149,435
+26,731
| +22% | +$1.15M | 0.01% | 1617 |
|
|
2017
Q3 | $5.26M | Buy |
122,704
+112,385
| +1,089% | +$4.21M | 0.01% | 1642 |
|
|
2017
Q2 | $382K | Buy |
10,319
+5,765
| +127% | +$255K | ﹤0.01% | 2935 |
|
|
2017
Q1 | $247K | Sell |
4,554
-61,120
| -93% | -$3.18M | ﹤0.01% | 3127 |
|
|
2016
Q4 | $3.49M | Buy |
65,674
+19,870
| +43% | +$1.13M | 0.01% | 1576 |
|
|
2016
Q3 | $2.78M | Buy |
45,804
+31,210
| +214% | +$1.94M | ﹤0.01% | 1721 |
|
|
2016
Q2 | $961K | Sell |
14,594
-155,442
| -91% | -$9.87M | ﹤0.01% | 2189 |
|
|
2016
Q1 | $9.64M | Buy |
170,036
+149,409
| +724% | +$16.8M | 0.02% | 854 |
|
|
2015
Q4 | $4.85M | Sell |
20,627
-30,329
| -60% | -$6.61M | 0.01% | 1379 |
|
|
2015
Q3 | $8.06M | Buy |
50,956
+14,058
| +38% | +$3.98M | 0.02% | 1059 |
|
|
2015
Q2 | $14M | Sell |
36,898
-101,133
| -73% | -$40.2M | 0.03% | 789 |
|
|
2015
Q1 | $57.7M | Buy |
138,031
+132,813
| +2,545% | +$47.5M | 0.11% | 215 |
|
|
2014
Q4 | $1.43M | Buy |
5,218
+4,498
| +625% | +$1.12M | ﹤0.01% | 2237 |
|
|
2014
Q3 | $140K | Buy |
+720
| New | +$157K | ﹤0.01% | 3498 |
|
|
2014
Q2 | – | Sell |
-17,327
| Closed | -$4.59M | – | 3444 |
|
|
2014
Q1 | $4.59M | Buy |
17,327
+16,554
| +2,142% | +$6.34M | 0.01% | 1248 |
|
|
2013
Q4 | $281K | Sell |
773
-13,647
| -95% | -$5.26M | ﹤0.01% | 3078 |
|
|
2013
Q3 | $7.66M | Sell |
14,420
-1,264
| -8% | -$433K | 0.02% | 862 |
|
|
2013
Q2 | $3.67M | Buy |
+15,684
| New | +$3.09M | 0.01% | 1217 |
|
Other funds holding CLDX
KCM
VCM
CC
EP
Millennium Management's CLDX Position: Q1 2026 in Review
Millennium Management increased its Celldex Therapeutics (CLDX) stake by 3.4% in Q1 2026, buying an estimated $1.11M and bringing the position to 1,253,532 shares worth $39.8M. The position accounts for 0.02% of the portfolio, ranked #1003.
Millennium Management first reported a position in CLDX in Q2 2013 and has held it in 41 quarters since. The position peaked at $57.7M in Q1 2015. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.
- Millennium Management held 1,253,532 shares of Celldex Therapeutics worth $39.8M as of Q1 2026.
- Millennium Management bought 40,827 Celldex Therapeutics shares in Q1 2026, an estimated $1.11M.
- Celldex Therapeutics made up 0.02% of Millennium Management's portfolio in Q1 2026, its #1003 holding.
- Millennium Management first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 41 quarters since.
- Millennium Management's Celldex Therapeutics position peaked at $57.7M in Q1 2015.
- 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.
Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.